憎水性栀子蓝色素制备的研究

以浓盐酸为催化剂,采用乙酸酐酯化处理水溶性栀子蓝色素,制备了憎水性栀子蓝色素.探讨了栀子蓝色素与乙酸酐料液比、反应时间和反应温度等因素对憎水性栀子蓝色素色价的影响.结果表明:采用料液比1:20,在常温下反应4 h,为制备憎水性栀子蓝色素的最优条件.同时,通过红外光谱、可见吸收光谱及溶解性对栀子蓝色素的酯化改性进行了初步的探讨.     

海底天然气管道投产案例分析

为防止形成天然气水合物，天然气管道在投产前必须彻底干燥。海底管道距离长，不能分段施工，多采用清管器组加干燥剂的作业方案，这就存在清管器组的运行控制、卡球和窜漏等问题，作业难度高、风险大。针对我国海底输气管道投产前干燥施工过程中出现的憋压、卡球、窜漏和清管器磨损等问题进行了分析，说明了发生问题的原因。对比研究了不同管道干燥方案的优缺点、清管器使用的合理性、干燥剂使用效果和干燥指标的制定与监测方法等问题。在此基础上， 提出了针对海底天然气管道的凝胶、干燥剂和多盘清管器的组合干燥方案。该方案能有效解决密封、卡球和凝胶滞留等问题，并能确保施工质量，对类似工程有借鉴意义。     

用土壤含水层处理系统去除水库微污染有机物的试验研究

本文针对当前中国饮用水源污染以微污染为主的特点，以北京三家店水库原水和永定河河道砂为研究对象，设计了用于表征土壤含水层处理系统的一维土柱，进行污水净化效果的试验研究。结果表明，土壤含水层处理系统对三家店水库微污染水中的有机物有一定的去除效果，在0．12m／d的水力负荷条件下，对CODMo去除率虽然仅为15％，但是出水达到了地表水Ⅱ类水质标准；对BOD5的去除率达到了55％，可以被有效地去除。渗透速率相同时，水力负荷周期对去除效果的影响不明显，但在保证一定水力负荷的情况下，可适当延长落干期，恢复土壤的渗透能力，达到较好的处理效果。同时，土壤含水层处理系统的净化能力主要发生在土层50cm以内。     

煤巷锚杆支护技术的探讨

从巷道围岩强度,原岩自重应力,地质构适应力,煤柱留设宽度和巷道断面形状等方面对影响煤巷稳定性的因素进行了分析,提出了煤巷锚杆支护注意的6个问题。     

嵌入式Web服务器在中小水电信息采集系统中的应用

中小水电站大多数建在偏远山区，并网管理难度非常大，解决中小水电站的信息传输是主要的技术难点之一。随着计算机技术的发展，嵌入式Web服务器技术在远程监控和实时通信系统中的应用越来越广泛。将Web技术引入中小水电站信息采集系统中，可以实现对中小水电站基于浏览器方式的远程监控。文中结合中小水电站通信结构，介绍了嵌入式Web服务器技术在中小水电站信息采集系统中的应用。     

求非线性方程近似解的逐次迭代法

本文提出了求解非线性问题的一种新方法——逐次迭代法，本方法先是给出一个初始近似解，然后将这个近似解进行校正迭代，使之接近于真实解，把一个非线性问题转化为一个线性问题来解决。     

工业废水中金属元素的测定

工业废水中金属离子对水环境造成污染,并危及人体健康,应准确进行测定.论述了原子吸收分光光度法测定工业废水中金属元素的原理,重点论述了测定Zn的条件、范围、干扰等因素,总结了测定锌的条件及测定结果;实验证明,用原子吸收分光光度法测定工业废水中的Zn元素,可取得较好的结果.     

Experimental Study on Polymer Artificial Bone with HA Coated and Fiber Liners

1Introduction HA(hydroxyapatite)wasakindofbioactiveceram ics,whichhadexcellentbiocompatibilityandtissueaffin ityinthatitscomponentsweresimilartothoseofhuman bone[1].Soitwasthebestknownhumanbonesubstitute,andunprecedentedeffecthadbeenharvestedinrecenttwo d…     

实用钢筋混凝土梁板结构优化设计

本文比较全面地考虑了钢筋混凝土梁板结构实际设计时的全部必要约束,给出了一套(单跨矩形和T形梁、单向板、按弹性理论计算的双向板和矩形等截面连续梁)简单实用的近优化设计的解析公式,为编制其优化设计的实用程序和图表提供了根据.     

Epidemiology of hepatitis C and G in sporadic and familial porphyria cutanea tarda

From 1995 to 1997, we prospectively evaluated the prevalence of hepatitis C virus (HCV) RNA in 124 patients with porphyria cutanea tarda (PCT) from Northern France (83 sporadic and 41 familial PCT). Serum samples were analyzed for ferritin, transaminases, HCV antibodies, and HCV RNA. In addition, genotyping of HCV and searches for HCV infection risk factors (blood transfusion, iv drug abuse, and surgical intervention) were performed. Twenty-six of 124 patients (21%; 95% CI: 13.9-28) were positive for serum HCV antibodies. All of them were also positive for HCV RNA. The prevalence of HCV infection was higher in the sporadic PCT group (26.5%, 22 out of 83) than in the familial PCT group (9.7%, 4 out of 41). Risk factors for hepatitis C infection were found to be significantly increased in the HCV-positive group when compared with the HCV-negative PCT group. In all HCV-positive patients with a risk factor, the suspected date of exposure to the virus always preceded the clinical onset of PCT. The HCV genotype pattern in PCT patients was similar to that observed in nonporphyric HCV patients in western European countries. Serum ferritin level was increased in both HCV-positive and HCV-negative porphyric patients. Transaminase levels were significantly higher in HCV-infected PCT patients. Sixty-seven out of 124 patients were retrospectively studied for hepatitis G virus (HGV) infection. Six of these 67 patients (8.9%; 95% CI: 2.1-15.8) were positive for HGV RNA. None of the six HGV-infected patients were positive for HCV RNA. The HGV-infected patients did not differ statistically from those without HGV infection with regard to age, ferritin, transaminase levels, and PCT treatment. These results support the view that sporadic cases of HGV infection may occur frequently. This study of a large cohort of HCV and PCT patients further documents an increasing gradient in HCV prevalence from northern to southern Europe, and shows that HCV infection acts as a triggering factor of PCT. Finally, the HGV prevalence found in the PCT patients was comparable with that found in French blood donors, suggesting that HGV is not a PCT triggering factor.